Why the study?
Outcome data and genotype-phenotype correlations for FLNC-related cardiomyopathy in children are scarce.
Do FLNC truncating variants increase the risk of adverse cardiovascular outcomes compared to non-truncating variants in children with FLNC-related cardiomyopathy?
Cohort (n=74)
Yes
Do FLNC truncating variants increase the risk of adverse cardiovascular outcomes compared to non-truncating variants in children with FLNC-related cardiomyopathy?
Childhood-onset FLNC-related cardiomyopathy carries a poor prognosis, with truncating variants acting as an independent predictor of adverse cardiovascular outcomes.
Answers are grounded in this paper and cite their sources.
FLNCtv may support risk stratification in childhood cardiomyopathy; leaves open whether genotype should guide management before prospective validation.
Filamin C (FLNC) contributes to 1%-8% of adult-onset cardiomyopathy (CMP), with a high prevalence of end-stage heart failure and sudden cardiac death, particularly for FLNC truncating variants (FLNCtv), rendering it one of the high-risk CMP genes. Outcome data and genotype-phenotype correlation in children are scarce. We conducted a retrospective cohort study of children (< 18 years) with CMP features and a (likely) pathogenic FLNC variant, identified via literature search or in the Belgian Pediatric Cardiology Registry (BePCaR), to evaluate cardiovascular outcomes and genotype-phenotype correlations. Seventy-four individuals (56.8% male, median age 4.5 years) from 57 families were included. Restrictive CMP was the most prevalent phenotype. Half of the patients experienced major adverse cardiovascular events, including heart transplantation (20.3%) and death (13.5%). Hypertrophic CMP was exclusively associated with ROD2 domain variants. Mortality was significantly higher in FLNCtv carriers versus non-truncating carriers (26.9% vs. 6.3%, p = 0.019), and multivariate analysis identified FLNCtv as an independent predictor of adverse outcome (OR = 6.4, 95% CI: [1.36, 29.80]). Extracardiac manifestations occurred in 32.4%, predominantly in RCM patients, with myopathy-associated variants clustering in exons 21 and 41. Pathogenic FLNC variants associate with early-onset CMP and poor prognosis, underscoring the need for early genetic screening, risk stratification, and personalized follow-up to improve outcome.
No takes yet. Share an insight, caveat, or question.
Cansse et al. (2026) conducted a cohort in Childhood-Onset Filamin c Related Cardiomyopathy (n=74). FLNC truncating variants (FLNCtv) vs. Non-truncating FLNC variants was evaluated on Mortality and adverse outcome (OR 6.4, 95% CI 1.36-29.80, p=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: